A PHASE 3 OPEN-LABEL TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS AND YOUNG CHILDREN IN CHINA WHO ARE NAIVE TO PNEUMOCOCCAL VACCINATION
Latest Information Update: 07 Nov 2024
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Hib vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Pfizer
- 17 Aug 2021 Status changed from recruiting to active, no longer recruiting.
- 04 Mar 2021 Planned End Date changed from 14 Feb 2024 to 31 Dec 2023.
- 04 Mar 2021 Planned primary completion date changed from 1 Nov 2021 to 27 Oct 2021.